SOPHiA DDM for Hereditary Cancers Enables Krsnaa Diagnostics to Expand its NGS Offerings
SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced that Krsnaa Diagnostics, India’s largest diagnostic services provider in radiology and pathology, is live on SOPHiA DDM technology. Krsnaa Diagnostics is using the SOPHiA DDM for Hereditary Cancers Solution to expand their current next-generation sequencing (NGS) offerings.
AiThority Interview Insights: AiThority Interview with Oji Udezue, Chief Product Officer at Typeform
“At SOPHiA GENETICS we pride ourselves on collaborating with cutting-edge laboratories and research institutions and working with them to bring data-driven medicine closer to all”
Hereditary causes account for approximately 10 percent of cancer cases1 and identification of individuals with suspected hereditable cancer can lead to preventative examinations and additional discussions with their physicians. Next-generation sequencing (NGS) is transforming the way genomic evaluation of hereditary cancers is performed and integrated into the daily workflow of clinical and research laboratories around the world. SOPHiA DDM™ for Hereditary Cancers Solution enables Krsnaa to provide high-quality NGS tests that help to evaluate for hereditary cancers.
Read More about AiThority Interview: AiThority Interview with Kyle Wong, Chief Strategy Officer at Emplifi
Krsnaa works to be accessible and affordable to anyone who seeks a high-quality NGS test. With SOPHiA GENETICS technology Krsnaa will advance its NGS offerings and help to democratize data-driven medicine.
“At SOPHiA GENETICS we pride ourselves on collaborating with cutting-edge laboratories and research institutions and working with them to bring data-driven medicine closer to all,” said Ken Freedman, Chief Revenue Officer, SOPHiA GENETICS. “Krsnaa is working to make precision medicine a reality for everyone in India and we are honored to support their work by offering our Hereditary Cancer Solution to expand their NGS offerings.”
The use of next-generation sequencing (NGS) aids significantly in detecting biomarkers for hereditary cancers but also provides a vast and complex dataset for analysis. The SOPHiA DDM™ for Hereditary Cancers Solution uses artificial intelligence and machine learning with patented technologies to analyze raw NGS data, making it faster and easier for experts to analyze and interpret findings from NGS data with confidence.
Latest AiThority Interview Insights : AiThority Interview with Jon Zimmerman, Chief Executive Officer at Holon Solutions
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.